Atlas Trials

Metastatic Gastric Adenocarcinoma

27 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Metastatic Gastric Adenocarcinoma

RecordFirmDate
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153)M.D. Anderson Cancer Center2022-02-14
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction (NCT04840264)Sixth Affiliated Hospital, Sun Yat-sen University2022-01-07
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760)Academic and Community Cancer Research United2021-06-16
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer (NCT04781686)Zhou Fuxiang2021-05-14
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (NCT03641313)National Cancer Institute (NCI)2020-11-16
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (NCT04248452)ECOG-ACRIN Cancer Research Group2020-05-26
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744)Mayo Clinic2020-02-13
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer (NCT04220827)M.D. Anderson Cancer Center2019-12-06
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer (NCT03918499)City of Hope Medical Center2019-04-19
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites (NCT03990103)China Medical University, China2017-11-01
Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA (NCT03116555)China Medical University, China2017-04-05
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma (NCT02539225)Eli Lilly and Company2015-10-05
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (NCT02314117)Eli Lilly and Company2015-01-20
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C (NCT02391038)Millennium Pharmaceuticals, Inc.2014-12-01

Track Metastatic Gastric Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.